Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) EBIT (2020 - 2025)

Historic EBIT for iSpecimen (ISPC) over the last 6 years, with Q3 2025 value amounting to -$2.8 million.

  • iSpecimen's EBIT fell 6595.61% to -$2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.1 million, marking a year-over-year decrease of 2430.55%. This contributed to the annual value of -$12.7 million for FY2024, which is 1395.51% down from last year.
  • Per iSpecimen's latest filing, its EBIT stood at -$2.8 million for Q3 2025, which was down 6595.61% from -$1.8 million recorded in Q2 2025.
  • iSpecimen's EBIT's 5-year high stood at -$942644.0 during Q1 2021, with a 5-year trough of -$5.8 million in Q4 2024.
  • In the last 5 years, iSpecimen's EBIT had a median value of -$2.2 million in 2023 and averaged -$2.4 million.
  • As far as peak fluctuations go, iSpecimen's EBIT plummeted by 40114.78% in 2021, and later surged by 4539.65% in 2025.
  • Over the past 5 years, iSpecimen's EBIT (Quarter) stood at -$2.0 million in 2021, then dropped by 7.35% to -$2.1 million in 2022, then tumbled by 34.06% to -$2.9 million in 2023, then plummeted by 103.43% to -$5.8 million in 2024, then skyrocketed by 51.54% to -$2.8 million in 2025.
  • Its EBIT stands at -$2.8 million for Q3 2025, versus -$1.8 million for Q2 2025 and -$1.6 million for Q1 2025.